Enanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Third Quarter Ended June 30, 2023
July 31 2023 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for viral infections, today announced that it plans to report its
financial results for its fiscal third quarter ended June 30, 2023
after the U.S. market closes on August 7, 2023. Enanta management
will host a conference call at 4:30 p.m. ET to discuss these
results and provide an update on the company’s business and
research and development pipeline.
Conference Call and Webcast Information
The live webcast can be accessed under "Events &
Presentations" in the investors section of Enanta’s website. To
join by phone, participants can register for the call here. It is
recommended that participants register a day in advance or at a
minimum of 15 minutes before the call. Once registered,
participants will receive an email with the dial-in information.
The archived webcast will be available on Enanta’s website for
approximately 30 days following the event.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for the treatment of viral
infections. Enanta’s research and development programs include
clinical candidates for the following disease targets: respiratory
syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus
(HBV). Enanta is also conducting research on a single agent
targeting both RSV and human metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis c virus infection and is sold by AbbVie in numerous
countries under the tradenames MAVYRET® (U.S.) and MAVIRET®
(ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com
for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230731318563/en/
Media and Investors Contact Jennifer Viera 617-744-3848
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Nov 2023 to Nov 2024
